Lord, Abbett & Co
EBS icon

Lord, Abbett & Co’s Emergent Biosolutions EBS Stock Holding History

Lord, Abbett & Co’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-341,864
Closed -$35.3M – 665
2020
Q3 		$35.3M Buy
+341,864
New +$36.9M 0.11% 276
2019
Q2 		– Sell
-139,420
Closed -$7.04M – 772
2019
Q1 		$7.04M Sell
139,420
-166,831
-54% -$9.84M 0.02% 614
2018
Q4 		$18.2M Buy
+306,251
New +$19.7M 0.07% 407
2016
Q3 		– Sell
-86,120
Closed -$2.42M – 884
2016
Q2 		$2.42M Sell
86,120
-10,553
-11% -$414K 0.01% 820
2016
Q1 		$3.51M Buy
+96,673
New +$3.41M 0.01% 767

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lord, Abbett & Co's EBS Position: Q4 2020 in Review

Lord, Abbett & Co sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 341,864 shares — an estimated $35.3M sold.

Lord, Abbett & Co first reported a position in EBS in Q1 2016 and held it in 5 quarters. The position peaked at $35.3M in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Lord, Abbett & Co reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
  • Lord, Abbett & Co sold 341,864 Emergent Biosolutions shares in Q4 2020, an estimated $35.3M.
  • Lord, Abbett & Co first reported a position in Emergent Biosolutions in Q1 2016 and held it in 5 quarters.
  • Lord, Abbett & Co's Emergent Biosolutions position peaked at $35.3M in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Lord, Abbett & Co's 13F filing for Q4 2020, filed 9 Feb 2021.